Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 30;8(9):959–970. doi: 10.1002/sctm.18-0222

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. stem cells translational medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Amelioration of acute kidney injury‐derived renal damages by therapeutic treatments. The levels of (A) NGAL, (B) KIM‐1, (C) cystatin C, and (D) caspase‐3 in the harvested kidney post‐treatment were determined by enzyme‐linked immunosorbent assay. All of treatment significantly reduced protein level the each marker with a statistical difference compared with saline treatment (analysis of variance [ANOVA], p < .0001; *, Tukey post hoc test at p < .05 with saline). Additionally, CM, HPSC, and CM + PRP treatment significantly reduced cystatin C (C) and caspase‐3 protein (D) compared with that of PRP treatment (ANOVA, p < .0001; *, Tukey post hoc test at p < .05; *, with saline; **, with PRP). Abbreviations: AMC, age‐matched control; CM, conditioned medium; HPSC, human placental stem cell; NGAL, neutrophil gelatinase‐associated lipocalin; PRP, platelet‐rich plasma.